Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 870-873

  Nadaraja, Sambavy ^a   Mamoudou, Aissata Diop ^a   Thomassen, Harald ^b   Wehner, Peder Skov ^c   Rosthoej, Steen ^a   Schroeder, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute lymphoblastic leukemia; Child; Methotrexate; Nausea; Palonosetron; Vomiting

Indexed keywords

DEXAMETHASONE; GRANISETRON; METHOTREXATE; METOPIMAZINE; ONDANSETRON; PALONOSETRON;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; CHILDHOOD LEUKEMIA; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INFANT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SINGLE DRUG DOSE; THERAPY DELAY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; HUMANS; ISOQUINOLINES; MALE; METHOTREXATE; NAUSEA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 84866147766     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24068     Document Type: Article

References (21)

1. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
2. Morrow GR. Chemotherapy-related nausea and vomiting: Etiology and management. CA Cancer J Clin 1989; 39: 89-104.
3. Zeltzer LK, Dolgin MJ, LeBaron S, et al. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics 1991; 88: 34-42.
4. de Boer-Dennert M, de WR, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. Br J Cancer 1997; 76: 1055-1061.
5. Hedstrom M, Haglund K, Skolin I, et al. Distressing events for children and adolescents with cancer: Child, parent, and nurse perceptions. J Pediatr Oncol Nurs 2003; 20: 120-132.
6. Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006; 106: 931-940.
7. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61: 162-175.
8. Cefalo MG, Ruggiero A, Maurizi P, et al. Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer. J Chemother 2009; 21: 605-610.
9. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 2008; 39: 601-606.
10. Navari RM. Palonosetron: A second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol 2009; 5: 1577-1586.
11. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
12. Gralla R, Lichinitser M, Van D, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
13. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
14. Kris MG, Urba SG, Schwartzberg LS. Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: A post-MASCC 2010. Clin Adv Hematol Oncol 2011; 9: suppl. 1-15.
15. Roila F, Feyer P, Maranzano E, et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 2005; 13: 129-131.
16. Small BE, Holdsworth MT, Raisch DW, Winter SS. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 2000; 22: 125-132.
17. Kadota R, Shen V, Messinger Y. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: A multicenter, stratified, double-blind, phase 3, randomized study. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 9570.
18. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-124.
19. Komada Y, Matsuyama T, Takao A, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer 1999; 35: 1095-1101.
20. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice. Oncologist 1999; 4: 191-196.
21. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: Focus on recent developments. Drugs 2009; 69: 515-533.